Institute for Integrative Therapies joins COMPASS Pathways PTSD psilocybin trial

The Institute for Integrative Therapies in Eden Prairie, Minnesota, has been selected as a site for COMPASS Pathways’ late-stage study of its investigational psilocybin treatment for PTSD. The trial widens IIT’s psychedelic research into a new psychiatric condition as COMPASS advances COMP360 through a multicenter Phase 2b/3 program.

Why it matters: - The selection puts the Institute for Integrative Therapies in a late-stage clinical program testing a potential psilocybin treatment for post-traumatic stress disorder. - The move expands IIT’s research portfolio beyond depression and into PTSD, a condition with substantial unmet treatment needs. - COMP202 could help clarify whether COMP360 may be useful for PTSD and how psychedelic medicines might fit into psychiatric care.

What happened: - The Institute for Integrative Therapies said Aug. 11, 2026, that COMPASS Pathways selected the Eden Prairie, Minnesota, center as a clinical trial site for COMP202, also called the Redefine Study. - COMP202 is COMPASS Pathways’ late-stage Phase 2b/3 trial of investigational COMP360 psilocybin treatment in adults with PTSD. - The study will be IIT’s first clinical trial focused on PTSD.

The details: - COMP202 is a multicenter, randomized, double-blind, controlled study with an open-label extension. - The trial is designed to evaluate the efficacy, safety and tolerability of COMP360 in participants with PTSD. - COMP360 is COMPASS Pathways’ proprietary synthetic formulation of psilocybin. - COMP360 remains investigational and has not been approved by the FDA for PTSD. - IIT has previously studied treatment-resistant depression and major depressive disorder using investigational psilocybin, psilocin, DMT, ketamine and other emerging compounds. - IIT previously participated in COMPASS Pathways’ clinical development program for COMP360 in treatment-resistant depression. - IIT says it has built clinical and research infrastructure for interventional psychiatry and psychedelic medicine studies.

Between the lines: - The site selection suggests COMPASS Pathways is continuing to broaden its clinical network as it tests psilocybin in new indications. - For IIT, the PTSD study signals a strategy of building experience across multiple diagnoses, compounds and treatment models rather than focusing on a single disorder. - Manoj Doss, IIT’s founder and CEO and principal investigator, said the organization wants to better understand which patients may benefit and how psychedelic medicines can be integrated responsibly into clinical care.

What's next: - IIT said study eligibility and enrollment details will be announced when recruitment opens. - The broader COMP202 program will continue collecting data on COMP360’s efficacy, safety and tolerability in PTSD. - IIT plans to keep expanding its research across next-generation psychiatric treatments.

The bottom line: - IIT’s new role in COMPASS Pathways’ PTSD trial marks a meaningful expansion of psychedelic medicine research in Minnesota and a key step in testing psilocybin beyond depression.